CN103002890A - 靶向癌症干细胞的新的化合物和组合物 - Google Patents

靶向癌症干细胞的新的化合物和组合物 Download PDF

Info

Publication number
CN103002890A
CN103002890A CN2011800231072A CN201180023107A CN103002890A CN 103002890 A CN103002890 A CN 103002890A CN 2011800231072 A CN2011800231072 A CN 2011800231072A CN 201180023107 A CN201180023107 A CN 201180023107A CN 103002890 A CN103002890 A CN 103002890A
Authority
CN
China
Prior art keywords
polymorph
furan
cancer
naphtho
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800231072A
Other languages
English (en)
Chinese (zh)
Inventor
李嘉强
D.勒格特
李有志
李微
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1Globe Biomedical Co Ltd
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Priority to CN201710665153.1A priority Critical patent/CN107721958B/zh
Priority to CN201710613672.3A priority patent/CN107311969B/zh
Priority to CN201710613671.9A priority patent/CN107375260B/zh
Priority to CN201710134235.3A priority patent/CN106860443A/zh
Publication of CN103002890A publication Critical patent/CN103002890A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
CN2011800231072A 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物 Pending CN103002890A (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201710665153.1A CN107721958B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201710613672.3A CN107311969B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201710613671.9A CN107375260B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201710134235.3A CN106860443A (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31588610P 2010-03-19 2010-03-19
US31589010P 2010-03-19 2010-03-19
US61/315,890 2010-03-19
US61/315,886 2010-03-19
US32581410P 2010-04-19 2010-04-19
US61/325,814 2010-04-19
PCT/US2011/029281 WO2011116398A1 (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Related Child Applications (5)

Application Number Title Priority Date Filing Date
CN201710613671.9A Division CN107375260B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201710665153.1A Division CN107721958B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201710613672.3A Division CN107311969B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201710134235.3A Division CN106860443A (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201410101861.9A Division CN104016951B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的化合物和组合物

Publications (1)

Publication Number Publication Date
CN103002890A true CN103002890A (zh) 2013-03-27

Family

ID=47678419

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2011800231072A Pending CN103002890A (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201710613671.9A Active CN107375260B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201710665153.1A Active CN107721958B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710613671.9A Active CN107375260B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物
CN201710665153.1A Active CN107721958B (zh) 2010-03-19 2011-03-21 靶向癌症干细胞的新的化合物和组合物

Country Status (15)

Country Link
US (4) US9084766B2 (https=)
EP (1) EP2547334B1 (https=)
JP (1) JP5602935B2 (https=)
KR (2) KR101908208B1 (https=)
CN (3) CN103002890A (https=)
AU (2) AU2011227022C1 (https=)
BR (2) BR112012023661A2 (https=)
CA (2) CA2793526C (https=)
DK (1) DK2547334T3 (https=)
ES (1) ES2659541T3 (https=)
MX (2) MX394137B (https=)
NZ (1) NZ602328A (https=)
RU (1) RU2571661C2 (https=)
SG (1) SG184063A1 (https=)
WO (1) WO2011116398A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163284A (zh) * 2014-02-07 2016-11-23 北京强新生物科技有限公司 3‑取代的羰基萘并[2,3‑b]呋喃衍生物或其药学上可接受的盐
CN107847481A (zh) * 2015-06-03 2018-03-27 波士顿生物医药有限公司 包含癌症干性抑制剂的组合物和用于治疗癌症的免疫治疗剂

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
RU2571661C2 (ru) * 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
PT2547205T (pt) * 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Novos métodos para atingir células estaminais cancerígenas
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
US10005752B2 (en) 2014-06-09 2018-06-26 Kyoto Pharmaceutical Industries, Ltd. Anticancer agent
BR112017022269A2 (pt) 2015-04-17 2018-07-10 Boston Biomedical Inc métodos para tratar câncer
US20180085341A1 (en) 2015-04-17 2018-03-29 Boston Biomedical, Inc. Methods for treating cancer
WO2017013865A1 (ja) * 2015-07-17 2017-01-26 大日本住友製薬株式会社 ２－アセチル－４Ｈ，９Ｈ－ナフト［２，３－ｂ］フラン－４，９－ジオンの製造方法
WO2017079864A1 (en) * 2015-11-12 2017-05-18 Hangzhou Yier Biotech Co., Ltd. Treatment of cancers related to chronically active ras
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
WO2017160978A1 (en) 2016-03-15 2017-09-21 Boston Biomedical, Inc. Cell cultures and use thereof
JP2019519573A (ja) 2016-06-28 2019-07-11 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
CA3058162A1 (en) 2017-03-30 2018-10-04 Boston Biomedical, Inc. Compositions for treating and/or preventing cancer
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3865130A4 (en) 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026253A2 (en) * 2002-09-17 2004-04-01 Arqule, Inc. Novel lapacho compounds and methods of use thereof
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2009060282A2 (en) * 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1049490A1 (ru) * 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
RU2571661C2 (ru) * 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026253A2 (en) * 2002-09-17 2004-04-01 Arqule, Inc. Novel lapacho compounds and methods of use thereof
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2009036059A2 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel stat3 pathway inhibitors and cancer stem cell inhibitors
WO2009060282A2 (en) * 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163284A (zh) * 2014-02-07 2016-11-23 北京强新生物科技有限公司 3‑取代的羰基萘并[2,3‑b]呋喃衍生物或其药学上可接受的盐
US10017488B2 (en) 2014-02-07 2018-07-10 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof
US10683274B2 (en) 2014-02-07 2020-06-16 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof
CN107847481A (zh) * 2015-06-03 2018-03-27 波士顿生物医药有限公司 包含癌症干性抑制剂的组合物和用于治疗癌症的免疫治疗剂

Also Published As

Publication number Publication date
US20130034591A1 (en) 2013-02-07
EP2547334A1 (en) 2013-01-23
ES2659541T3 (es) 2018-03-16
EP2547334B1 (en) 2017-11-15
KR101714819B1 (ko) 2017-03-09
CN107721958B (zh) 2024-08-23
RU2571661C2 (ru) 2015-12-20
CN107375260B (zh) 2023-10-24
BR112012023661A2 (pt) 2020-11-24
RU2012144421A (ru) 2014-04-27
US20150183756A1 (en) 2015-07-02
MX2012010434A (es) 2013-01-29
KR20160135375A (ko) 2016-11-25
WO2011116398A1 (en) 2011-09-22
CN107375260A (zh) 2017-11-24
CA2946899A1 (en) 2011-09-22
CA2793526A1 (en) 2011-09-22
KR20130056227A (ko) 2013-05-29
US20160271099A1 (en) 2016-09-22
CA2946899C (en) 2018-03-06
MX394137B (es) 2025-03-24
JP5602935B2 (ja) 2014-10-08
AU2011227022A1 (en) 2012-09-27
NZ602328A (en) 2014-11-28
US20180193303A1 (en) 2018-07-12
SG184063A1 (en) 2012-10-30
AU2011227022B2 (en) 2015-11-19
CA2793526C (en) 2018-05-01
BR122021025776B1 (pt) 2022-12-27
AU2016200953A1 (en) 2016-03-03
KR101908208B1 (ko) 2018-10-15
AU2011227022C1 (en) 2016-04-21
MX370721B (es) 2019-12-20
CN107721958A (zh) 2018-02-23
US9084766B2 (en) 2015-07-21
US9381184B2 (en) 2016-07-05
JP2013522325A (ja) 2013-06-13
EP2547334A4 (en) 2013-08-14
AU2016200953B2 (en) 2017-07-27
DK2547334T3 (en) 2018-02-19

Similar Documents

Publication Publication Date Title
CN107721958B (zh) 靶向癌症干细胞的新的化合物和组合物
CN103025159A (zh) 靶向癌症干细胞的新方法
CN104016951B (zh) 靶向癌症干细胞的化合物和组合物
AU2015218436B2 (en) Novel Methods For Targeting Cancer Stem Cells
HK1239527A1 (en) Novel compounds and compositions for targeting cancer stem cells
HK1179535B (en) Novel compounds and compositions for targeting cancer stem cells
HK1179535A (en) Novel compounds and compositions for targeting cancer stem cells
HK1179478A (en) Novel methods for targeting cancer stem cells
HK1179478B (en) Novel methods for targeting cancer stem cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BEIJING QIANGXIN BIOTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: BOSTON BIOMEDICAL INC.

Effective date: 20131225

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; TO: 100083 HAIDIAN, BEIJING

TA01 Transfer of patent application right

Effective date of registration: 20131225

Address after: 100083 Beijing City, Haidian District Xueyuan Road No. 30, large industrial building B block 8 room 01-15

Applicant after: Beijing Qiangxin Biotechnology Co., Ltd.

Address before: Massachusetts, USA

Applicant before: Boston Biomedical, Inc.

RJ01 Rejection of invention patent application after publication

Application publication date: 20130327

RJ01 Rejection of invention patent application after publication